May cause hypoglycemia through additive effects when dosage exceeds maximum recommended daily amount.
Source: NLP:butalbital, aspirin, and caffeine
Brand names: Butalbital, Aspirin, And Caffeine
Nonsteroidal Anti-inflammatory Drug · Platelet Aggregation Inhibitor · Barbiturate · Central Nervous System Stimulant · Methylxanthine · Cyclooxygenase Inhibitors
Route: Oral
Contraindications
CONTRAINDICATIONS Butalbital, aspirin, and caffeine capsules are contraindicated under the following conditions: Hypersensitivity or intolerance to aspirin, caffeine, or butalbital. Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). Patients with the syndrome of nasal polyps, angioedema and bronchospastic reactivity to aspirin or other nonsteroidal anti-inflammatory drugs. Anaphylactoid reactions have occurred in such patients. Peptic ulcer or other serious gastrointestinal lesions. Patients with porphyria.
Pregnancy & Breastfeeding
Pregnancy Risk Summary Withdrawal seizures were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last 2 months of pregnancy. Butalbital was found in the infant’s serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further seizure or other withdrawal symptoms. Use of NSAIDs, including Butalbital, Aspirin, and Caffeine Capsules, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Because of these risks, limit dose and duration of Butalbital, Aspirin, and Caffeine Capsules use between about 20 and 30 weeks of gestation, and avoid Butalbital, Aspirin, and Caffeine Capsules use at about 30 weeks of gestation and later in pregnancy [see WARNINGS; Fetal Toxicity ]. Premature Closure of Fetal Ductus Arteriosus Use of NSAIDs, including Butalbital, Aspirin, and Caffeine Capsules at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment. Animal reproduction studies have been conducted with Butalbital, Aspirin, and Caffeine Capsules. It is also not known whether Butalbital, Aspirin, and Caffeine Capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Butalbital, Aspirin, and Caffeine Capsules should be given to a pregnant woman only when clearly needed. Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization. In animal studies, administration of prostaglandin synthesis inhibitors such as aspirin, resulted in increased pre- and post-implementation l
17 interactions on record
May cause hypoglycemia through additive effects when dosage exceeds maximum recommended daily amount.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with alcohol.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with tranquilizers such as chlordiazepoxide.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with other CNS depressants.
Source: NLP:butalbital, aspirin, and caffeine
May cause hypoglycemia through additive effects when dosage exceeds maximum recommended daily amount.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin causes bone marrow toxicity and blood dyscrasias by displacing from secondary binding sites.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin causes bone marrow toxicity and blood dyscrasias by displacing from binding sites and reducing its excretion.
Source: NLP:butalbital, aspirin, and caffeine
CNS effects of butalbital may be enhanced by MAO inhibitors.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin increases risk of peptic ulceration and bleeding with additive effects.
Source: NLP:butalbital, aspirin, and caffeine
Causes increased CNS depression.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin enhances effects causing bleeding by inhibiting prothrombin formation and displacing anticoagulants from plasma protein binding sites.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with other narcotic analgesics.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with sedative-hypnotics.
Source: NLP:butalbital, aspirin, and caffeine
Butalbital causes increased CNS depression when combined with general anesthetics.
Source: NLP:butalbital, aspirin, and caffeine
Withdrawal of corticosteroids in chronic aspirin users may result in salicylism. Corticosteroids enhance renal clearance of salicylates.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin diminishes effectiveness of uricosuric agents in gout treatment by competing for protein binding sites.
Source: NLP:butalbital, aspirin, and caffeine
Aspirin diminishes effectiveness of uricosuric agents in gout treatment by competing for protein binding sites.
Source: NLP:butalbital, aspirin, and caffeine